Product Description
Mechanisms of Action: KRAS G12D Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Jiangxi Kvvit Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07689539 |
DN022150-302 | P3 |
Not yet recruiting |
Pancreatic Cancer |
2028-07-01 |
3% |
2026-07-09 |
|
NCT07656376 |
DN022150-301 | P3 |
Not yet recruiting |
Pancreatic Cancer |
2029-02-07 |
9% |
2026-06-19 |
Recent News Events
Date |
Type |
Title |
|---|